Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Cash & Equivalents data on record, last reported at $195.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 38.87% year-over-year to $195.0 million; the TTM value through Dec 2025 reached $195.0 million, down 38.87%, while the annual FY2025 figure was $195.0 million, 38.87% down from the prior year.
  • Cash & Equivalents reached $195.0 million in Q4 2025 per INDV's latest filing, down from $445.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $510.0 million in Q2 2025 and bottomed at $195.0 million in Q4 2025.
  • Average Cash & Equivalents over 3 years is $359.5 million, with a median of $345.5 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: increased 0.95% in 2024, then plummeted 38.87% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $316.0 million in 2023, then grew by 0.95% to $319.0 million in 2024, then crashed by 38.87% to $195.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $195.0 million in Q4 2025, $445.0 million in Q3 2025, and $510.0 million in Q2 2025.